Taletrectinib Cost-Effectiveness Analysis for ROS1+ NSCLC in the U.S.

A United States-based cost-effectiveness analysis of four treatment strategies for ROS1-positive non-small cell lung cancer. The dataset, published by Gengwei Huo on figshare in April 2026, contains results from a partitioned survival model, including incremental cost-effectiveness ratios (ICERs) and quality-adjusted life years (QALYs) for strategies involving taletrectinib and chemotherapy.

Use Cases

• Compare incremental cost-effectiveness ratios (ICERs) for different drug administration sequences based on the model results.
• Analyze the impact of drug pricing on cost-effectiveness outcomes based on the sensitivity analysis described.
• Evaluate quality-adjusted life year (QALY) gains for first-line versus second-line targeted therapies.
• Assess treatment strategies against a defined willingness-to-pay (WTP) threshold of $150,000 per QALY.

Strengths

• Specific ICER and QALY results are provided, such as a first-line strategy adding 4.61372 QALYs at an additional cost of $1,263,183.95.
• Analysis is based on a partitioned survival model using costs and utility values from reputable literature and public databases.
• Includes sensitivity analysis identifying taletrectinib cost as the primary driver of the ICER results.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• The dataset is a 287.5 KB DOC file, indicating a very limited scope, likely containing summary tables rather than raw patient-level data.

Provenance

Source

figshare

Collection Method

Constructed from a partitioned survival model using literature and public cost data.

Time Range

Analysis timeframe is not specified.

Freshness

Last updated 2026-04-13 04:35:13; freshness should be verified.

Geography

United States